logo
Share SHARE
FONT-SIZE Plus   Neg

AVI BioPharma's Eteplirsen Meets PrimaryEndpoint For Duchenne Muscular Dystrophy

AVI BioPharma Inc. (AVII: Quote), a developer of RNA-based therapeutics, reported that treatment with eteplirsen met the primary efficacy endpoint in a randomized, double-blind, placebo-controlled Phase IIb study in boys with Duchenne muscular dystrophy or DMD. Eteplirsen administered once weekly at 30mg/kg over 24 weeks resulted in a statistically significant increase in novel dystrophin compared to no increase in the placebo group.

In the study, a shorter duration of eteplirsen treatment, 12 weeks, did not show a significant increase in novel dystrophin, despite administration of the drug at a higher dose, the company added. This finding suggests that a longer duration of dosing is required before meaningful levels of dystrophin are produced.

Eteplirsen is AVI's lead drug candidate that is systemically delivered for the treatment of a substantial subgroup of patients with DMD.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Firearms maker Smith & Wesson Holding Corp. (SWHC), Tuesday reported a drop in profit for the third quarter, as revenues and margins declined reflecting lower sales of long guns. However, earnings for the quarter came in ahead of Wall Street estimates as did revenues. Moving ahead, the company boosted... Target Corp (TGT) on Tuesday said it plans $2 billion of cost savings over the next two years, mainly at its corporate headquarters, as the discount retailer strives to boost profit and become a leaner outfit. Reports said that about $500 million of the savings would occur in the current year, and... Bob Evans Farms Inc. (BOBE) on Tuesday reported a drop in a profit for the third quarter, despite growth in revenues, with both earnings and revenues falling short of expectations. Moving head, the restaurant chain lowered its fiscal year 2015 outlook. Shares of Bob Evans Farms plunged over 18 percent...
comments powered by Disqus
Follow RTT